Sign in
Taking people in New ZealandPhase 3

Tests inotuzumab ozogamicin added to chemo-immunotherapy in high-risk childhood B-cell leukemia

Tests inotuzumab ozogamicin with chemo-immunotherapy in people with high-risk B-cell acute lymphoblastic leukemia.

Key facts

Who runs it
Children's Oncology Group
Where
Christchurch and Grafton, New ZealandSee the 2 sitesAlso in 4 other countries, 229 sites
Trial code
Registry title
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status
Recruiting
Phase
Phase 3
People taking part
5,951 people, planned
Started
31 Oct 2019
Expected to end
31 Mar 2032
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Biospecimen Collection
  • Blinatumomab
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Bone Scan
  • Calaspargase Pegol
  • Computed Tomography
  • Cyclophosphamide
  • Cytarabine
  • Daunorubicin Hydrochloride
  • Dexamethasone
  • Doxorubicin Hydrochloride
  • Inotuzumab Ozogamicin
  • Leucovorin Calcium
  • Magnetic Resonance Imaging
  • Mercaptopurine
  • Methotrexate
  • Pegaspargase
  • Positron Emission Tomography
  • Prednisolone
  • Prednisone
  • Questionnaire Administration
  • Radiation Therapy
  • Thioguanine
  • Vincristine Sulfate
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), mixed phenotype acute leukemia (MPAL) or B-lymphoblastic lymphoma (B-LLy). It tests adding inotuzumab ozogamicin to chemotherapy.

Age
Older than 365 days and younger than 25 years.
Sex
All sexes can join.
Disease stage
Newly diagnosed B-ALL or MPAL with at least 25% blasts in the bone marrow, or newly diagnosed B-LLy Murphy stage III or IV. B-LLy stage I or II can join only with steroid pretreatment. B-ALL at age 1-9.99 years needs a white blood cell count of 50,000/uL or more, or testicular leukemia, CNS leukemia (CNS3) or steroid pretreatment. B-ALL at age 10-24.99 years can have any white blood cell count.
Earlier treatment
No earlier cytotoxic chemotherapy for this or any earlier cancer. Steroid pretreatment, steroid cytoreduction and intrathecal cytarabine are allowed. No more than 72 hours of hydroxyurea in the week before treatment starts.
Biomarker or test result
Not required. Central confirmation of the MPAL diagnosis must happen within 22 days of enrollment.

Main reasons for not taking part

  • Down syndrome
  • Acute undifferentiated leukemia, T-lymphoblastic lymphoma or lymphoma that cannot be classified
  • Known Charcot-Marie-Tooth disease
  • Known MYC translocation linked to mature (Burkitt) B-cell ALL
  • Pregnancy, or breastfeeding during the study and for 2 months after the last inotuzumab ozogamicin dose

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • B-ALL and MPAL patients must be enrolled on APEC14B1 and consented to eligibility studies (Part A) prior to treatment and enrollment on AALL1732. Note that central confirmation of MPAL diagnosis must occur within 22 days of enrollment for suspected MPAL patients. If not performed within this time frame, patients will be taken off protocol
  • APEC14B1 is not a requirement for B-LLy patients but for institutional compliance every patient should be offered participation in APEC14B1. B-LLy patients may directly enroll on AALL1732
  • Patients must be > 365 days and < 25 years of age
  • Initial white blood cell count (WBC) criteria for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy):; Age 1-9.99 years: WBC >= 50,000/uL; Age 10-24.99 years: Any WBC; Age 1-9.99 years: WBC < 50,000/uL with one or more of the following:; Testicular leukemia; CNS leukemia (CNS3); Steroid pretreatment
  • Initial white blood cell count (WBC) criteria for patients with MPAL (within 7 days prior to the start of protocol-directed systemic therapy):; Age 1-24.99 years: any WBC NOTE: Patients enrolled as suspected MPAL but found on central confirmatory testing to have B-ALL must meet the B-ALL criteria above (age, WBC, extramedullary disease, steroid pretreatment) to switch to the B-ALL stratum before the end of induction
  • Patient has newly diagnosed B-ALL or MPAL (by World Health Organization [WHO] 2016 criteria) with >= 25% blasts on a bone marrow (BM) aspirate; OR If a BM aspirate is not obtained or is not diagnostic of acute leukemia, the diagnosis can be established by a pathologic diagnosis of acute leukemia on a BM biopsy; OR A complete blood count (CBC) documenting the presence of at least 1,000/uL circulating leukemic cells if a bone marrow aspirate or biopsy cannot be performed
  • Patient has newly diagnosed B-LLy Murphy stages III or IV
  • Patient has newly diagnosed B-LLy Murphy stages I or II with steroid pretreatment
  • Note: For B-LLy patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to B-ALL. For tissue processed by other means (i.e., paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of B-LLy defined by the submitting institution will be accepted
  • Central nervous system (CNS) status must be determined prior to enrollment based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment and cytoreduction. Note that once cerebrospinal fluid (CSF) has been collected, protocol therapy can be initiated while final determination of CNS status is pending. It is recommended that intrathecal cytarabine be administered at the time of the diagnostic lumbar puncture. This is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture. This is allowed prior to enrollment. Systemic chemotherapy must begin within 72 hours of this intrathecal therapy
  • Direct bilirubin < 2.0 mg/dL (34 micromoles/L)
  • Alanine aminotransferase (ALT) ≤ 10x upper limit of normal (ULN). For the purposes of this study, the ULN for ALT is defined as 45 U/L
  • Exceptions to this include patients with known Gilbert's Syndrome, or those with hepatic involvement from leukemic or lymphomatous infiltration
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, Food and Drug Administration (FDA), and NCI requirements for human studies must be met

Who cannot take part

  • With the exception of steroid pretreatment and steroid cytoreduction or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for the current diagnosis of B-ALL, MPAL, or B-LLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL1732
  • Patients who have received > 72 hours of hydroxyurea within one week prior to start of systemic protocol therapy
  • For Murphy stage III/IV B-LLy patients, or stage I/II patients with steroid pretreatment, the following additional exclusion criteria apply:; T-lymphoblastic lymphoma; Morphologically unclassifiable lymphoma; Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma
  • Patients requiring radiation at diagnosis
  • Female patients who are pregnant, since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
  • Patients with Down syndrome are not eligible
  • Patients with known Charcot-Marie-Tooth disease
  • Patients with B-ALL or MPAL who do not have sufficient diagnostic bone marrow submitted for APEC14B1 testing and who do not have a peripheral blood sample submitted containing > 1,000/uL circulating leukemia cells
  • Patients with acute undifferentiated leukemia (AUL) are not eligible
  • Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype
  • Lactating women who plan to breastfeed their infants while on study and for 2 months after the last dose of inotuzumab ozogamicin
  • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of study participation. For those patients randomized to inotuzumab ozogamicin, there is a minimum of 8 months after the last dose of inotuzumab ozogamicin for females and 5 months after the last dose of inotuzumab ozogamicin for males

This trial is currently available in New Zealand.

Also in 4 other countries, 229 sites

  • Christchurch HospitalChristchurch, New ZealandContact: Siobhan F. Cross (principal investigator)Taking people
  • Starship Children's HospitalGrafton, New ZealandContact: Lochie R. Teague (principal investigator)Taking people

About the trial

What the trial wants to find out

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protein that can bind to certain targets on the surface of cells. Inotuzumab ozogamicin is a monoclonal antibody that is linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells by binding to the CD22 protein on the surface of the cancer cell and delivering calicheamicin inside the cells to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blinatumomab is a specialized type of monoclonal antibody known as a bispecific T-cell engager (BiTE). It works by simultaneously binding to CD19 on cancer cells and CD3 on normal immune cells, bringing them together to destroy leukemia cells. Blinatumomab is a standard part of chemo-immunotherapy treatment for B-ALL. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin or blinatumomab.

Read full original descriptionShow less

The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemo-immunotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first phase of therapy: Induction. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-induction treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (consolidation, blinatumomab block 1, interim maintenance 1, blinatumomab block 2, delayed intensification, interim maintenance 2, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of consolidation or part of delayed intensification. Other aims of this study include evaluating 1) side effects of treatment using patient-reported outcomes and health-related quality of life, 2) the best ways to help patients adhere to oral chemotherapy regimens, 3) the relationship between levels of inotuzumab ozogamicin in the blood and side effects, 4) the impact of chemo-immunotherapy on the immune system and risk of infection, and 5) the impact of social determinants of health on outcomes. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.

The 4 groups in the trial

  • Arm D (CD 22 positive HR B-ALL)Existing treatment, for comparison

    See detailed description for Arm D.

    Treatment: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, and Vincristine Sulfate

  • Arm E (CD22 positive HR B-ALL)Treatment being tested

    See detailed description for Arm E.

    Treatment: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, and Vincristine Sulfate

  • Arm I (MPAL)Treatment being tested

    See Detailed Description for Arm I.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, and Vincristine Sulfate

  • Arm II (B-LLy)Treatment being tested

    See Detailed Description for Arm II.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, and Questionnaire Administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Plain-language title
Tests inotuzumab ozogamicin added to chemo-immunotherapy in high-risk childhood B-cell leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
25 August 2026